Skip to main content

Table 2 Univariate analysis of prognostic factors in patients with rectal adenocarcinoma undergoing surgery

From: Nomogram to predict cause-specific mortality of patients with rectal adenocarcinoma undergoing surgery: a competing risk analysis

Variables Classification Cause-specific death (%) Death due to other causes (%)
1-year (95% CI) 3-year (95% CI) 5-year (95% CI) P value 1-year (95% CI) 3-year (95% CI) 5-year (95% CI) P value
Age      < 0.001     < 0.001
  < 65 2.39 (2.34–2.45) 12.21 (11.95–12.48) 21.55 (21.08–22.02)   0.67 (0.65–0.68) 2.04 (1.99–2.09) 3.39 (3.30–3.47)  
  ≥ 65 7.39 (7.17–7.60) 19.41 (18.88–19.94) 27.43 (26.70–28.16)   3.70 (3.58–3.81) 9.04 (8.76–9.31) 14.39 (13.93–14.85)  
Race      < 0.001     0.0027
  White 4.44 (4.37–4.50) 14.92 (14.70–15.14) 23.34 (23.00–23.69)   1.99 (1.96–2.02) 5.04 (4.96–5.12) 8.14 (8.00–8.29)  
  Black 5.23 (4.39–6.06) 19.36 (16.48–22.25) 30.72 (26.31–35.12)   1.99 (1.66–2.31) 5.53 (4.60–6.47) 8.38 (6.85–9.90)  
  Other 3.86 (3.41–4.31) 14.10 (12.49–15.71) 23.89 (21.16–26.63)   1.22 (1.07–1.36) 3.63 (3.17–4.09) 6.58 (5.67–7.50)  
Sex      0.1107     0.1401
  Male 4.42 (4.32–4.51) 15.05 (14.75–15.35) 24.28 (23.79–24.76)   1.96 (1.91–2.00) 4.90 (4.79–5.01) 8.19 (7.99–8.38)  
  Female 4.46 (4.32–4.60) 15.36 (14.90–15.83) 23.51 (22.80–24.22)   1.83 (1.77–1.89) 4.97 (4.80–5.13) 7.70 (7.43–7.98)  
MS      < 0.001     < 0.001
  Married 3.40 (3.34–3.47) 12.76 (12.51–13.02) 20.87 (20.45–21.29)   1.50 (1.47–1.53) 3.80 (3.72–3.88) 6.51 (6.36–6.67)  
  Unmarried 6.08 (5.89–6.28) 19.06 (18.49–19.63) 29.00 (28.15–29.85)   2.56 (2.47–2.64) 6.74 (6.51–6.97) 10.40 (10.02–10.78)  
AJCC      < 0.001     < 0.001
  I 1.76 (1.64–1.87) 4.23 (3.94–4.51) 7.93 (7.36–8.49)   2.00 (1.87–2.13) 5.52 (5.16–5.89) 9.77 (9.09–10.45)  
  II 2.67 (2.55–2.79) 9.52 (9.09–9.95) 16.42 (15.66–17.19)   1.99 (1.90–2.08) 5.28 (5.04–5.53) 9.30 (8.83–9.76)  
  III 4.21 (4.08–4.34) 15.74 (15.29–16.20) 26.14 (25.38–26.89)   1.77 (1.71–1.82) 4.56 (4.42–4.71) 6.80 (6.56–7.04)  
  IV 15.82 (14.06–17.58) 51.47 (47.83–55.11) 70.71 (67.22–74.19)   2.05 (1.78–2.31) 4.21 (3.65–4.77) 5.38 (4.62–6.14)  
TS      < 0.001     0.0007
  < 4 cm 2.93 (2.85–3.02) 11.48 (11.15–11.80) 19.47 (18.91–20.02)   1.72 (1.67–1.77) 4.46 (4.33–4.60) 7.28 (7.04–7.51)  
  4–8 cm 5.15 (5.01–5.28) 17.41 (16.98–17.84) 26.74 (26.09–27.39)   2.16 (2.10–2.22) 5.44 (5.29–5.59) 8.74 (8.48–9.01)  
  ≥ 8 cm 8.40 (7.16–9.64) 22.38 (19.31–25.46) 32.87 (28.38–37.37)   1.41 (1.18–1.63) 4.44 (3.68–5.19) 7.61 (6.18–9.04)  
LN      < 0.001     < 0.001
  0 2.59 (2.54–2.65) 8.65 (8.47–8.84) 14.74 (14.41–15.06)   1.83 (1.79–1.87) 4.95 (4.84–5.05) 8.73 (8.52–8.94)  
  1–3 5.19 (4.91–5.46) 19.25 (18.30–20.19) 31.39 (29.92–32.85)   1.98 (1.87–2.09) 4.76 (4.49–5.03) 6.93 (6.51–7.35)  
  4–8 9.33 (8.27–10.39) 30.34 (27.51–33.17) 44.68 (41.06–48.30)   2.28 (2.00–2.56) 5.59 (4.90–6.28) 7.40 (6.45–8.35)  
  > 8 15.10 (11.19–19.01) 48.35 (40.20–56.51) 62.11 (53.82–70.40)   1.75 (1.22–2.27) 3.93 (2.74–5.12) 4.99 (3.41–6.57)  
Radiation      < 0.001     < 0.001
  None 7.95 (7.66–8.24) 20.13 (19.45–20.80) 27.27 (26.37–28.16)   3.47 (3.34–3.61) 8.20 (7.89–8.51) 12.51 (12.02–13.01)  
  Yes 2.70 (2.65–2.76) 12.71 (12.47–12.95) 22.36 (21.94–22.79)   1.14 (1.11–1.16) 3.29 (3.23–3.36) 5.69 (5.56–5.82)  
Chemotherapy      < 0.001     < 0.001
  None 7.91 (7.56–8.26) 16.34 (15.66–17.03) 22.00 (21.08–22.91)   3.91 (3.73–4.09) 9.25 (8.83–9.67) 14.26 (13.59–14.92)  
  Yes 3.13 (3.08–3.19) 14.76 (14.51–15.01) 24.84 (24.42–25.26)   1.15 (1.13–1.17) 3.27 (3.21–3.33) 5.53 (5.41–5.64)  
  1. MS, marital status; TS, tumor size; LN, number of metastasis lymph nodes